BRIEF published on 08/06/2024 at 22:10, 1 year 3 months ago Nyxoah Reports Financial Results for Q2 and H1 2024 Revenue Growth Capital Raise Operational Highlights FDA Submission Q2 2024 Results
PRESS RELEASE published on 08/06/2024 at 22:05, 1 year 3 months ago Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results Nyxoah SA reports financial and operating results for the second quarter and first half of 2024, including FDA submission completion and U.S. approval progress Financial Results Operating Results FDA Submission Nyxoah SA U.S. Approval
BRIEF published on 07/15/2024 at 08:20, 1 year 4 months ago Nyxoah Appoints Scott Holstine as Chief Commercial Officer FDA Approval Medical Device Industry Nyxoah Obstructive Sleep Apnea Scott Holstine
PRESS RELEASE published on 07/15/2024 at 08:15, 1 year 4 months ago Nyxoah Appoints Scott Holstine as Chief Commercial Officer Nyxoah appoints Scott Holstine as Chief Commercial Officer, bringing 26 years of medical device industry experience. His role is crucial for Nyxoah's U.S. launch success in treating Obstructive Sleep Apnea Chief Commercial Officer Medical Technology Nyxoah Obstructive Sleep Apnea Scott Holstine
BRIEF published on 07/03/2024 at 12:35, 1 year 5 months ago Nyxoah Signs €37.5 Million Loan Agreement with European Investment Bank Loan Agreement Medical Technology European Investment Bank Nyxoah Obstructive Sleep Apnea
PRESS RELEASE published on 07/03/2024 at 12:30, 1 year 5 months ago Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Nyxoah signs a €37.5 million loan facility agreement with the European Investment Bank to boost research, development, and manufacturing capacity for sleep apnea solutions Research And Development European Investment Bank Sleep Apnea Nyxoah €37.5 Million Loan
Published on 12/05/2025 at 02:35, 3 hours 49 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 24 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 19 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 24 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 54 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 33 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 59 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 9 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 13 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 24 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 39 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 40 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 23 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
